EGFR and non-small cell lung carcinoma: Given the persistent challenge of secondary resistance to EGFR‐TKI in treating EGFR‐mutated NSCLC, we established drug‐resistant cell models (HCC827OR and H1975OR) for Osimertinib, as detailed in the “ Experimental Section”, to investigate targeted treatment strategies.